Antacids may be given concomitantly if needed.
In adult patients with moderate (creatinine clearance <50 mL/min) or severe (creatinine clearance <10 mL/min) renal insufficiency, the elimination half-life of famotidine is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of famotidine may be reduced to half the dose or the dosing interval may be prolonged to 36-48 hours as indicated by the patient’s clinical response.
Based on the comparison of pharmacokinetic parameters for famotidine in adults and pediatric patients, dosage adjustment in pediatric patients with moderate or severe renal insufficiency should be considered.
Bottle of 30 (NDC 61442-121-30)
Bottle of 100 (NDC 61442-121-01)
Bottle of 500 (NDC 61442-121-05)
Bottle of 1,000 (NDC 61442-121-10)
Bottle of 30 (NDC 61442-122-30)
Bottle of 100 (NDC 61442-122-01)
Bottle of 500 (NDC 61442-122-05)
Bottle of 1,000 (NDC 61442-122-10)
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Manufactured and Distributed by:
Carlsbad Technology, Inc.
Carlsbad, CA 92008
Revised: 06/12CTI-12 Rev. C
Principal Display Panel – Bottle Label
|FAMOTIDINE famotidine tablet|
|Labeler — Dispensing Solutions, Inc. (066070785)|
|Registrant — PSS World Medical, Inc. (101822682)|
|Dispensing Solutions, Inc.||066070785||relabel (66336-187), repack (66336-187)|
Revised: 10/2013 Dispensing Solutions, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.